“Surge in the prevalence of narcolepsy globally, implementation of reimbursement policies related to narcolepsy, and narcolepsy awareness programs and services drive the growth of the global narcolepsy drugs market.”
The global narcolepsy drugs market garnered $2.43 billion in 2018, and is expected to reach $5.36 billion by 2026, growing at a CAGR of 10.3% from 2019 to 2026. The research provides an extensive analysis of changing market trends, key segments, drivers & opportunities, key winning strategies, and competitive landscape.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/3612
Surge in the prevalence of narcolepsy globally, implementation of reimbursement policies related to narcolepsy, and narcolepsy awareness programs and services drive the growth of the market. However, ill effects and risks regarding narcolepsy drugs and delay in diagnosis or misdiagnosis hinder the market growth. On the other hand, untapped potential in developing nations would create new opportunities in the coming years.
The daytime extreme sleepiness segment accounted for the highest market share in 2018, holding nearly half of the total market, owing to increase in prevalence of narcolepsy and other disorders related to sleep. However, the cataplexia segment is expected to register the highest CAGR of 10.7% during the forecast period, owing to loss of muscle control by patients of cataplexia, and nearly 70% of narcolepsy patients suffer from this symptom.
The selective serotonin reuptake inhibitor segment is expected to grow at the fastest CAGR of 11.3% throughout the forecast period, owing to rise in R&D activities for developing these types of drugs. However, the sodium oxybate segment held the major share in the market in 2018, contributing more than half of the total market, owing to highly effective nature of these drugs for treatment of daytime extreme sleepiness and cataplexy.
The market across the Asia-Pacific region would grow at the fastest rate with a CAGR of 11.4% during the forecast period, owing to rise in prevalence of narcolepsy and increase in adoption rate of narcolepsy drugs. However, the market across North America accounted for the highest share in 2018, accounting for more than two-fifths of the total share, owing to increase in number of narcolepsy and other sleep disorders in the region.
The key players analyzed in the report include:
- Addrenex Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Ligand Pharmaceuticals
- Jazz Pharmaceuticals Plc.
- Shire Plc
- Graymark Healthcare, Inc.
- Arena Pharmaceuticals
- Bioprojet.
Key Findings of the Narcolepsy Drugs Market:
- Based on disease type, the cataplexia segment is expected to experience rapid growth in the market, and is projected to grow at a highest CAGR from 2019 to 2026.
- Depending on disease type, the daytime extreme sleepiness segment holds the highest share in 2018, and is anticipated to continue this trend during the forecast period.
- By therapeutics type, the sodium oxybate segment was the major revenue contributor in 2018, and is anticipated to continue this trend during the forecast period.
- Asia-Pacific region is anticipated to grow at high CAGR during the forecast period.
Scope of the Report
| Report Attribute | Details |
| Market size available for years | 2019-2026 |
| Base year considered | 2020 |
| Forecast period | 2020-2026 |
| Forecast units | Value (USD) |
| Segments covered | Type and Therapeutics Type |
| Geographies covered | North America, Europe, Asia-Pacific, LAMEA |
Related Report
Non-Alcoholic Steatohepatitis (NASH) Market by Drug Type (Vitamin E & Pioglitazone, Ocaliva, Elafibranor, and Selonsertib & Cenicriviroc), and Sales Channel (Hospital Pharmacy, Online Provider, and Retail Pharmacy) – Global Opportunity Analysis and Industry Forecast, 2021-2025
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/224
Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agent/Diuretic, and Other Drugs) – Global Opportunity Analysis and Industry Forecast, 2017-2023
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/4602
Contact
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com
Read More @ https://www.alliedmarketresearch.com/press-release/narcolepsy-drugs-market.html